About Us
About Haihe Biopharma

Haihe Biopharma is a leading innovation-driven biotechnology company in China. Focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide.

As a new drug R&D company led by an academician of the Chinese Academy of Engineering, Haihe Biopharma is committed to the path of independent innovation. It also has a research and management team with a global perspective, and it is proactively mapping out the international development of innovative drugs.

Currently, seven of the 9 core products in the Haihe's R&D pipeline  have entered the clinical development stage, and four have obtained IND approval from the US FDA.

With support from top venture capitalists in life science and technology, Haihe is accelerating the clinical development and commercialization of innovative products, and strives to provide patients with safer and more effective drugs at the earliest possible time.

Mission and Vision
Our Mission:
Inclusive and open to diversity,
innovation oriented to win together and benefit the mankind.
Our Vision:
Guided by biomarkers,
we aim to address the unmet clinical needs and provide patients
with safer and more effective innovative drugs.

 

Management Team
Company Milestones

Haihe Biopharma is a leading innovation-driven biotechnology company in China. Focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs, Haihe brings life-saving therapies to cancer patients worldwide.

  •  

    July 2020

    Haihe completed
    Haihe completed worth
    1.2 billion yuan Series B Funding

  •  

    July 2020

    Haihe completed the reorganization of related group companies. Shanghai Haihe Pharmaceutical Research and Development Co Ltd acquired the stakes of Shanghai RMX Biopharma Co Ltd.

  •  

    December 2019

    Haihe established its US office

  •  

    October 2019

    Haihe’s Manufacturing Hub set foot in Taizhou China Medical City, with planned investment of 600 million yuan

  •  

    September 2019

    Haihe was recognized as Shanghai’s New & Hi-Tech Enterprise
     

  •  

    April 2019

    Haihe completed the first patient dosing of oral paclitaxel RMX3001 phase III clinical trial for advanced gastric cancer

  •  

    February 2019

    Haihe completed Haihe completed $136.6 million Series A Funding

  •  

    January 2019

    The pivotal Phase IIb clinical trial of first-class innovative drug Lucitanib for patients with thymic cancer completed the enrollment of the first patient in China

  •  

    September 2018

    Haihe reached strategic cooperation agreements with Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tigermed, Junshi Biosciences, 3D Medicines, and Jiuzhou Pharmaceutical

  •  

    March 2018

    Haihe Pharmaceutical merged with Nuomaixi Pharmaceutical to form Haihe Biopharma Co, Ltd.

Awards
2019
2018
XXX XXX
XXX
XXX
Follow Us
©2020 Haihe Biopharma Co., Ltd.
All Rights Reserved 沪ICP备12016151号-1